Introduction: Bone is the most common site of hematogenous metastasis of malignant tumors. Patients with bone metastasis can have a series of bone related adverse events, which seriously affect the quality of life and survival time of patients. Imaging examination is the main means of clinical diagnosis and evaluation of bone metastasis. Aim of the Work: To evaluate the value of single-photon emission computerized tomography (SPECT) combined with CT and MRI in the diagnosis of bone metastasis of malignant tumors. Subjects and Methods: Eighty patients with bone metastasis from malignant tumors who were admitted to Affiliated Hospital of Chengde Medical College were selected from March 2019 to June 2021. They underwent bone scan with SPECT imaging, CT and MRI separately. The distribution of bone metastasis from primary tumors as well as efficacy of the above three detection methods for bone metastasis was analyzed. Results: A total of 464 lesions were detected by SPECT and CT in the same scanning field, with SPECT detection rate of 92.5% (429/464) and CT detection rate of 77.8% (361/464) (P < 0.05). In addition, 143 lesions were detected by SPECT beyond the same scanning field. A total of 321 lesions were detected by SPECT and MRI in the same scanning field, with SPECT detection rate of 95.6% (307/321) and MRI detection rate of 82.6% (265/321) (P < 0.05), and nother 286 lesions were detected by SPECT beyond the same scanning field. In all, 259 lesions were detected by CT and MRI scans in the wild same scanning field. The detection rate was 71.4% (185/259) for CT, and 95.7% (248/259) for MRI (P < 0.05). The ensitivity, specificity and accuracy of SPECT imaging combined with CT and MRI were higher than single SPECT imaging, CT and MRI (P < 0.05). Conclusion: SPECT may be the preferred screening modality for uspected bone metastases, and when combined with CT and MRI, it can clarify the regional distribution of bone metastasis from malignant tumors and improve the sensitivity, specificity and accuracy of diagnosis with high clinical significance.
References
[1]
Zhao, Z.Q., Ye, Z.P., Yan, T.Q., et al. (2017) Research Progress in Quality of Life Assessment of Patients with Bone Metastases. Chinese Journal of Orthopaedics, 37, 1177-1184.
[2]
Zhu, A.H. and Wang, R.F. (2016) Comparison of PET/CT and Whole Body Bone Imaging in the Diagnosis of Different Types of Bone Metastases. China Medical Imaging Technology, 32, 944-948.
[3]
Yang, Z., Yang, G.S., Li, N., et al. (2016) Diagnostic Value of Whole-Body Bone Imaging Combined with CA153 and CEA in Breast Cancer with Bone Metastasis. Chinese Journal of Cancer Prevention, 23, 1229-1233.
[4]
Zhang, L.Q., Qin, Y.F., Li, W., et al. (2017) Diagnosis of Bone Metastasis in Patients with High-Risk Prostate Cancer by Conventional SPECT/CT Tomography Fusion Imaging. China Medical Imaging Technology, 33, 260-264.
[5]
Sheng, F.J., Wang, M., Yang, L., et al. (2016) Comparative Analysis of I131 and Chemoradiotherapy in the Treatment of Bone Metastasis of Differentiated Thyroid Cancer and Its Impact on the Survival of Patients. Chinese Journal of Endemic Disease Prevention and Control, 31, 131-133.
[6]
Xiong, H.R., Zhou, Q., Zhang, J.H., et al. (2017) Short Term Efficacy and Safety of Mr Guided Focused Ultrasound in Relieving Pain of Bone Metastases. Chinese Journal of Radiology, 51, 446-450.
[7]
Ding, Y.Y., Shi, D.D., Zhu, Z.P., et al. (2017) Study on the Value of SPECT/CT Bone Tomographic Fusion Imaging in the Diagnosis of Tumor Bone Metastasis. Journal of Medical Imaging, 27, 527-530.
[8]
Niu, Y.J., Wen, Y.T., Shen, W.W., et al. (2014) Risk Factors for Bone Metas-Tasis in Patients with Primary Lung Cancer: Study Protocol for a Systematic Review. BMJ Open, 4, e005202. https://doi.org/10.1136/bmjopen-2014-005202
[9]
Li, L., Zhao, Z. and Guo, X. (2006) Imaging Diagnosis of Malignant Tumor Bone Metastasis. Chinese Journal of Nuclear Medicine, 26, 315-318.
[10]
Zhao, H., An, J.P., Xu, X.H., et al. (2011) Evaluation of Bone Metastasis of Prostate Cancer by Radionuclide Bone Imaging Combined with PSA, FPSA and FPSA/TPSA. Journal of Radioimmunology, 24, 176-178.
[11]
Wang, S.J., song, Y.R., Zheng, X.H., et al. (2008) Evaluation of the Efficacy of 153 SM EDTMP in the Treatment of Bone Metastases by Whole Body Bone Imaging. Modern Oncology Medicine, 16, 2177-2179.
[12]
You, M.Q., Wang, S.H., Jiang, C.F., et al. (2018) Clinical Analysis of Radioactive I125 Seed Implantation in Patients with Advanced Malignant Tumors after Radiotherapy and Chemotherapy. China Cancer Clinic and Rehabilitation, 25, 102-104.
